TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26088659

Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Atomoxetine alone or with a stimulant
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Antipsychotic usually together with a stimulant
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Other pharmacotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Indicated ADHD medication
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Antipsychotic
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: No pharmacotherapy
Number of subjects: 206
Study: 23782741

Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Contact-control intervention
Number of subjects: 35
Study: 22188761

Group type: EXPERIMENTAL
Intervention: ARA-enriched oil (240 or 720 mg ARA per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19395188

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) plus androgen deprivation therapy
Number of subjects: 284

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 284
Study: 16234828

Group type: EXPERIMENTAL
Intervention: Low GI/high DF bread
Number of subjects: 7

Group type: COMPARATOR
Intervention: High GI/low DF bread
Number of subjects: 7
Study: 15256239

Group type: EXPERIMENTAL
Intervention: FAMTX (5-Fluorouracil, doxorubicin, methotrexate)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 59
Study: 10905544

Group type: EXPERIMENTAL
Intervention: Daily fish meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 20:5 omega3) or docosahexaenoic acid (DHA, 22:6 omega3)
Number of subjects: 0
Study: 10168173

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 8163889

Group type: EXPERIMENTAL
Intervention: 0.2% hydrocortisone and 1.0% lignocaine hydrochloride no-touch aqueous spray
Number of subjects: 83
Study: 3098573

Group type: EXPERIMENTAL
Intervention: Ritanserin (serotonin-S2 antagonist), administered for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31304380

Group type: EXPERIMENTAL
Intervention: Kaia App (multidisciplinary mHealth back pain App) for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control treatment (six individual physiotherapy sessions over 6 weeks and high-quality online education)
Number of subjects: 101
Study: 29924421

Group type: EXPERIMENTAL
Intervention: In vivo exposure group treatment
Number of subjects: 43
Study: 27054681

Group type: EXPERIMENTAL
Intervention: RTI (Resistance Training with Instability)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RT (Resistance Training)
Number of subjects: 39

Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RTI
Number of subjects: 39
Study: 25493974

Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 882

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 882
Study: 22761453

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1521
Study: 20104528

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (ascorbic acid 120 mg, vitamin E 30 mg, beta‐carotene 6 mg, selenium 100 microg, zinc 20 mg)
Number of subjects: 12741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study: 18469433

Group type: EXPERIMENTAL
Intervention: Nurse-delivered contraceptives in the home
Number of subjects: 103

Group type: COMPARATOR
Intervention: Comparison group (not specified intervention)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Recruitment activities
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Retention activities
Number of subjects: 103
Study: 15272923

Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (R‐Exp)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clomiphene (150 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (Cl‐Exp)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: E2 treatment in Group 2 (30 days) plus R from days 21 to 30 (R‐Exp)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: E2 treatment in Group 2 (30 days) plus Cl from days 21 to 30 (Cl‐Exp)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cl addition (for 10 days) in Group 2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: R addition in Group 2
Number of subjects: 16
Study: 11434469

Group type: EXPERIMENTAL
Intervention: Low-power laser (LPL) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 60
Study: 9605676

Group type: EXPERIMENTAL
Intervention: Neutral head position
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Extended head position
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flexed head position
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no specific intervention)
Number of subjects: 18
Study: 7817728

Group type: EXPERIMENTAL
Intervention: Mothers experiencing stillbirth
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control mothers
Number of subjects: 210
Study: 2898052

Group type: EXPERIMENTAL
Intervention: B subunit killed whole-cell (BS-WC) vaccine
Number of subjects: 62285

Group type: EXPERIMENTAL
Intervention: Killed whole-cell-only (WC) vaccine
Number of subjects: 62285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62285
Study: 1199703

Group type: EXPERIMENTAL
Intervention: Human chorionic somatomammotropin (S HCS) concentration measured by radioimmunoassay
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: S HCS concentration
Number of subjects: 393
Study: 31721407

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL (JJ stent only)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard PCNL (nephrostomy tube and JJ stent)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 31186020

Group type: EXPERIMENTAL
Intervention: Time needed to harm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percent excess risk
Number of subjects: 0
Study: 28120485

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Triazolam 0.375 mg (positive control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 11
Study: 25399551

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) and trametinib (2 mg once daily)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib
Number of subjects: 704

Group type: COMPARATOR
Intervention: Vemurafenib
Number of subjects: 704
Study: 23234813

Group type: EXPERIMENTAL
Intervention: Oral recombinant human PTH(1‐31)NH(2) 5mg once daily for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous teriparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21664757

Group type: EXPERIMENTAL
Intervention: CRM intervention (n=26), receiving interactive video-based CRM-training
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control intervention (n=18), receiving an additional ALS-training
Number of subjects: 176
Study: 18287453

Group type: EXPERIMENTAL
Intervention: 1-mm interactive multiplanar reformation (MPR) images
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3-mm axial images
Number of subjects: 96
Study: 17263088

Group type: EXPERIMENTAL
Intervention: Soft drink containing 0.232 g of ginseng and 2 g of ginkgo extract
Number of subjects: 10
Study: 12963188

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 25

Group type: COMPARATOR
Intervention: CABG and OPCAB
Number of subjects: 25
Study: 10931020

Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continued treatment with MPFF
Number of subjects: 100
Study: 9283511

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (0.4 mg/kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: meta‐chlorophenylpiperazine (m‐CPP) (1.0 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 26
Study: 7685921

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) and transrectal ultrasonography (TRUS)
Number of subjects: 1284

Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 1284

Group type: COMPARATOR
Intervention: Prospective randomized trial
Number of subjects: 1284
Study: 3106458

Group type: EXPERIMENTAL
Intervention: Acute hpGRF‐44 iv administration (1 microgram/Kg bw)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Multiple iv administrations (1 microgram/kg bw at 09:30 and 21:30 h for 4 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sc administration of the same dose at 4‐h intervals by a programmable portable pump
Number of subjects: 23
Study: 31429757

Group type: EXPERIMENTAL
Intervention: Nrf2 target gene expression in bronchial epithelium of current smokers
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nrf2 target gene expression in alveolar macrophages
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nrf2 target gene expression in nasal epithelium
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nrf2 target gene expression in peripheral blood mononuclear cells (PBMCs)
Number of subjects: 89
Study: 29846100

Group type: EXPERIMENTAL
Intervention: FOLFIRI + cetuximab for eight cycles followed by cetuximab alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI + cetuximab
Number of subjects: 0
Study: 27583476

Group type: EXPERIMENTAL
Intervention: linagliptin 5mg/d
Number of subjects: 40
Study: 24833699

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate in 70% alcohol
Number of subjects: 750

Group type: COMPARATOR
Intervention: 10% povidone iodine in 70% alcohol
Number of subjects: 750
Study: 22489255

Group type: EXPERIMENTAL
Intervention: Risperidone (2.0 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20222968

Group type: EXPERIMENTAL
Intervention: Medifast's meal replacement program (MD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isocaloric, food‐based diet (FB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study: 18669979

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day + fenofibrate 160 mg/day
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg/day
Number of subjects: 611

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 611
Study: 16394908

Group type: EXPERIMENTAL
Intervention: Intravenous tPA and heparin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intra-arterial tPA
Number of subjects: 18
Study: 12873939

Group type: EXPERIMENTAL
Intervention: Ephedrine 210 microg/kg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 53
Study: 10567287

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 214

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Surgery and Angioplasty
Number of subjects: 214
Study: 8638025

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empiric amiodarone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type-I antiarrhythmic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed group of antiarrhythmic drugs
Number of subjects: 0
Study: 1887968

Group type: EXPERIMENTAL
Intervention: Clonidine 1.25 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine 0.625 micrograms/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 6693150

Group type: EXPERIMENTAL
Intervention: Baumanometer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Arteriosonde 1216
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Physiometrics SR‐2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Random‐zero
Number of subjects: 72
Study: 31738072

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for AUD, duration: 12 weeks
Number of subjects: 92
Study: 29551654

Group type: EXPERIMENTAL
Intervention: 2-week diabetes education program
Number of subjects: 29
Study: 26990318

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 20

Group type: COMPARATOR
Intervention: SST
Number of subjects: 20
Study: 24446216

Group type: EXPERIMENTAL
Intervention: Fufang Xuelian Burn Ointment (FXBO) plus common burn wound therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Common burn wound therapy
Number of subjects: 240
Study: 22390186

Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 127

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 127
Study: 20499223

Group type: EXPERIMENTAL
Intervention: Parental presence (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Parental absence (n = 31)
Number of subjects: 61
Study: 17493470

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day)
Number of subjects: 32
Study: 18159246

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding (non-EBF)
Number of subjects: 958
Study: 14667432

Group type: EXPERIMENTAL
Intervention: Expectancy challenge
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study: 10689269

Group type: EXPERIMENTAL
Intervention: Nondipper hypertensive patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dipper and nondipper groups
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dippers and nondippers
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nondipper patients
Number of subjects: 76
Study: 9288477

Group type: EXPERIMENTAL
Intervention: Comparison stimulus with varying loudness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference stimulus with fixed pulse rate
Number of subjects: 0
Study: 8472519

Group type: EXPERIMENTAL
Intervention: 600 mg tablet of ST‐679
Number of subjects: 0

Group type: COMPARATOR
Intervention: 600 mg capsule of ST‐679
Number of subjects: 0
Study: 3082297

Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous nasoduodenal feeding
Number of subjects: 100
Study: 31926340

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg and 40 mg
Number of subjects: 170
Study: 31413542

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5‐5 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28851434

Group type: EXPERIMENTAL
Intervention: ToyBox‐intervention (implemented for 6 weeks)
Number of subjects: 2438

Group type: EXPERIMENTAL
Intervention: High teachers process evaluation score
Number of subjects: 2438

Group type: EXPERIMENTAL
Intervention: Low teachers process evaluation score
Number of subjects: 2438

Group type: EXPERIMENTAL
Intervention: Parents' process evaluation score (low, medium, high)
Number of subjects: 2438
Study: 25743737

Group type: EXPERIMENTAL
Intervention: Exergame
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 22757665

Group type: EXPERIMENTAL
Intervention: 1540 nm non-ablative fractional laser (NAFL) treatment, 4 treatments at monthly intervals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1540 nm non-ablative fractional laser (NAFL) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NAFL treatment
Number of subjects: 24
Study: 21576636

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg orally twice a day) plus erlotinib (150 mg orally daily)
Number of subjects: 168

Group type: COMPARATOR
Intervention: placebo plus erlotinib (150 mg orally daily)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: sorafenib/erlotinib
Number of subjects: 168

Group type: COMPARATOR
Intervention: placebo/erlotinib
Number of subjects: 168
Study: 19589270

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 84
Study: 16466589

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (non-MCI subjects)
Number of subjects: 29
Study: 14586588

Group type: EXPERIMENTAL
Intervention: Noise exposure (75 dBA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Odor exposure (furfurylmercaptan)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined exposure (noise + odor)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Combined exposure vs. single exposures
Number of subjects: 9
Study: 10711927

Group type: EXPERIMENTAL
Intervention: Ondansetron (24 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15321287

Group type: EXPERIMENTAL
Intervention: Epidural morphine (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine patient‐controlled analgesia (PCA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine and Intravenous morphine patient‐controlled analgesia (PCA)
Number of subjects: 60
Study: 8242290

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 60
Study: 3899048

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (mean dosage, 141 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30204919

Group type: EXPERIMENTAL
Intervention: Online self-management program
Number of subjects: 289

Group type: COMPARATOR
Intervention: Online disease education program (control)
Number of subjects: 289
Study: 29790278

Group type: EXPERIMENTAL
Intervention: Split-dose 4-L polyethylene glycol (4-SD)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Routine, morning-only 2-L polyethylene glycol (2-MO)
Number of subjects: 187
Study: 27240140

Group type: EXPERIMENTAL
Intervention: Weight Watchers (WW)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nutrition Education (NE)
Number of subjects: 300
Study: 25261141

Group type: EXPERIMENTAL
Intervention: Walking frame with a porter and a nurse from the postanesthesia care unit to the general ward
Number of subjects: 22

Group type: COMPARATOR
Intervention: Transported in their beds
Number of subjects: 22
Study: 22320902

Group type: EXPERIMENTAL
Intervention: HVP (soluble highly viscous polysaccharide)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (skim milk powder)
Number of subjects: 54
Study: 20566719

Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus graft
Number of subjects: 164

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone graft
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Early reconstructions (<5 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Later reconstructions (>5 months)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Patients without medial meniscal surgery
Number of subjects: 164

Group type: COMPARATOR
Intervention: Patients with medial meniscal surgery
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Physical functioning in Short Form-36 for early-reconstructed patients
Number of subjects: 164

Group type: COMPARATOR
Intervention: Physical functioning in Short Form-36 for later-reconstructed patients
Number of subjects: 164
Study: 16996618

Group type: EXPERIMENTAL
Intervention: Balloon Dilatation (BD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Bicanalicular Silicone Tube Intubation (STI)
Number of subjects: 37
Study: 14766688

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 1 g
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 300
Study: 11575338

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lash reflex
Number of subjects: 90

Group type: COMPARATOR
Intervention: Loss of grip of a small metal cylinder
Number of subjects: 90

Group type: COMPARATOR
Intervention: Loss of voluntary finger tapping
Number of subjects: 90

Group type: COMPARATOR
Intervention: Loss of postural tone in an outstretched arm
Number of subjects: 90
Study: 9763047

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 8186139

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 4 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Itraconazole 100 mg daily for 4 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 83